1007882-13-4

Basic information

• Product Name: C₂₄H₃₂BF₂N₃O₄
• Synonyms: C₂₄H₃₂BF₂N₃O₄
• CAS NO: 1007882-13-4
• Molecular Weight: 475.344
• Mol File: 1007882-13-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: C₂₄H₃₂BF₂N₃O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₄H₃₂BF₂N₃O₄(1007882-13-4)
• EPA Substance Registry System: C₂₄H₃₂BF₂N₃O₄(1007882-13-4)

Safety Data

• Hazardous Substances Data: 1007882-13-4(Hazardous Substances Data)

Upstream product

• 1612854-21-3 C₁₈H₂₀BrF₂NO₅ 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 1007882-05-4 C₁₈H₂₀BrF₂N₃O₂ 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 1007882-05-4 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4,4-difluoropyrrolidine-1-carboxylate 

Downstream Products

• 1560643-28-8 C₃₅H₄₂BF₂N₃O₄ 
• 1560643-31-3 C₄₁H₄₆F₄N₆O₄ 
• 1560638-96-1 C₄₅H₅₂F₄N₈O₆ 
• 1560643-26-6 C₃₀H₃₀F₅N₃O₅S 
• 1613055-67-6 C₃₀H₃₀F₅N₃O₅S 
• 1613055-72-3 C₄₅H₄₈F₄N₆O₄ 
• 1334312-52-5 MK-8325 
• 1612854-23-5 C₃₄H₃₇F₅N₄O₇S 
• 1399843-28-7 C₂₆H₃₅BF₂N₄O₅ 
• 1612854-22-4 C₁₉H₂₄BF₂N₃O₂ 

Relevant articles and documents

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV

HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.